These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 18393849)
21. [Therapeutic targets in the treatment of dyslipidemia: HDL and non-HDL cholesterol]. Brea Hernando ÁJ Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():3-6. PubMed ID: 25043539 [TBL] [Abstract][Full Text] [Related]
22. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors? Page MM; Hooper AJ; Burnett JR Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232 [TBL] [Abstract][Full Text] [Related]
23. Treatment of Dyslipidemia in Diabetes: Recent Advances and Remaining Questions. Chait A; Goldberg I Curr Diab Rep; 2017 Sep; 17(11):112. PubMed ID: 28956258 [TBL] [Abstract][Full Text] [Related]
24. A Clinical Guide to Combination Lipid-Lowering Therapy. Russell C; Sheth S; Jacoby D Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190 [TBL] [Abstract][Full Text] [Related]
25. New Drugs for Atherosclerosis. Bruikman CS; Stoekenbroek RM; Hovingh GK; Kastelein JP Can J Cardiol; 2017 Mar; 33(3):350-357. PubMed ID: 27993452 [TBL] [Abstract][Full Text] [Related]
26. EP2300 compounds: focusing on the antiatherosclerotic properties of squalene synthase inhibitors. Tavridou A; Manolopoulos VG Curr Pharm Des; 2009; 15(27):3167-78. PubMed ID: 19754389 [TBL] [Abstract][Full Text] [Related]
31. New Therapeutic Approaches to the Treatment of Dyslipidemia. Rader DJ Cell Metab; 2016 Mar; 23(3):405-12. PubMed ID: 26853751 [TBL] [Abstract][Full Text] [Related]
32. The therapeutic role of niacin in dyslipidemia management. Boden WE; Sidhu MS; Toth PP J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242 [TBL] [Abstract][Full Text] [Related]
33. [Cholesterol metabolism modulators in future drug therapy for atherosclerosis]. Morozova S; Suc-Royer I; Auwerx J Med Sci (Paris); 2005 Dec; 21 Spec No():53-8. PubMed ID: 16598906 [TBL] [Abstract][Full Text] [Related]
34. Looking into the crystal ball-upcoming drugs for dyslipidemia. George M; Selvarajan S; Muthukumar R; Elangovan S J Cardiovasc Pharmacol Ther; 2015 Jan; 20(1):11-20. PubMed ID: 25079474 [TBL] [Abstract][Full Text] [Related]
35. Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Rizvi AA; Popovic DS; Papanas N; Pantea Stoian A; Al Mahmeed W; Sahebkar A; Janez A; Rizzo M Expert Rev Cardiovasc Ther; 2022 Jul; 20(7):515-527. PubMed ID: 35786159 [TBL] [Abstract][Full Text] [Related]
36. The treatment of dyslipidemia--what's left in the pipeline? Rau O; Zettl H; Popescu L; Steinhilber D; Schubert-Zsilavecz M ChemMedChem; 2008 Feb; 3(2):206-21. PubMed ID: 17963209 [TBL] [Abstract][Full Text] [Related]
37. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. Urban D; Pöss J; Böhm M; Laufs U J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703 [TBL] [Abstract][Full Text] [Related]